Want to see PRQR full AI Analyst Report?
Top Page
ProQR
(NASDAQ:PRQR)
Select Model
Select Model
Rating:52Neutral
Price Target:
$1.50
▼(-36.97% Downside)
Action:Reiterated
Date:08/17/26
The score is primarily held back by weak financial performance—large ongoing losses and substantial negative free cash flow dominate despite strong gross margins and improving revenue. Technicals provide support with price above major moving averages and moderately positive momentum, but elevated volatility (high beta) adds risk. Valuation is constrained by negative earnings and the absence of a dividend yield.
Positive Factors
AI-enabled RNA editing platform
The integration of AI into Axiomer has already produced a clinical-stage candidate with improved editing efficiency versus a prior molecule. This could strengthen discovery productivity, shorten development cycles, and expand the platform’s ability to generate multiple programs over time.
Negative Factors
Persistent losses and cash burn
Large ongoing losses and deeply negative operating and free cash flow show that the business is not self-funding. Continued development spending therefore consumes capital and can require additional financing over time, reducing financial flexibility if programs take longer or cost more to advance.
Read all positive and negative factors
Positive Factors
Negative Factors
AI-enabled RNA editing platform
The integration of AI into Axiomer has already produced a clinical-stage candidate with improved editing efficiency versus a prior molecule. This could strengthen discovery productivity, shorten development cycles, and expand the platform’s ability to generate multiple programs over time.
Read all positive factors
ProQR (PRQR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$225.77M
Dividend YieldN/A
Average Volume (3M)720.50K
Price to Earnings (P/E)―
Beta (1Y)2.29
Revenue Growth19.49%
EPS Growth-4.53%
CountryUS
Employees166
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.40
Shares Outstanding138,087,650
10 Day Avg. Volume723,922
30 Day Avg. Volume720,505
Financial Highlights & Ratios
PEG Ratio-0.38
Price to Book (P/B)3.12
Price to Sales (P/S)11.85
P/FCF Ratio-3.37
Enterprise Value/Market Cap0.38
Enterprise Value/Revenue4.61
Enterprise Value/Gross Profit5.00
Enterprise Value/Ebitda-2.91
Forecast
1Y Price Target
$8.25Price Target Upside246.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$16.70M
ProQR Business Overview & Revenue Model
Company Description
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical ...
How the Company Makes Money
ProQR primarily generates revenue from collaboration arrangements and licensing-related payments tied to its RNA-therapeutics programs and platform, rather than from product sales (it has historically not been a commercial-stage company with marke...
ProQR Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
63
Positive
Cash Flow
29
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 18.57M | 15.28M | 18.91M | 6.51M | 3.59M | 1.33M |
| Gross Profit | 17.15M | 12.68M | 18.91M | 6.51M | 3.59M | 1.33M |
| EBITDA | -29.44M | -37.04M | -24.12M | -24.10M | -56.46M | -54.95M |
| Net Income | -42.40M | -40.52M | -27.76M | -28.12M | -64.42M | -60.74M |
Balance Sheet | ||||||
| Total Assets | 133.50M | 132.43M | 173.92M | 152.31M | 182.84M | 238.33M |
| Cash, Cash Equivalents and Short-Term Investments | 117.08M | 108.53M | 154.71M | 131.37M | 101.15M | 213.25M |
| Total Debt | 13.19M | 16.43M | 16.08M | 21.80M | 23.45M | 68.66M |
| Total Liabilities | 54.05M | 74.44M | 82.22M | 106.59M | 111.68M | 109.57M |
| Stockholders Equity | 79.44M | 57.99M | 91.70M | 45.72M | 71.58M | 129.45M |
Cash Flow | ||||||
| Free Cash Flow | -50.29M | -53.81M | -37.81M | 20.18M | -69.22M | -26.50M |
| Operating Cash Flow | -49.14M | -52.79M | -36.39M | 21.55M | -68.51M | -26.01M |
| Investing Cash Flow | -1.15M | -1.02M | -4.07M | 4.28M | -702.00K | -425.00K |
| Financing Cash Flow | 48.04M | -1.84M | 70.28M | -2.27M | -30.89M | 136.83M |
ProQR Technical Analysis
Negative
2.38
Price Trends
1.93
Negative
1.78
Negative
1.75
Negative
Market Momentum
-0.10
Positive
32.10
Neutral
20.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRQR, the sentiment is Negative. The current price of 2.38 is above the 20-day moving average (MA) of 1.81, above the 50-day MA of 1.93, and above the 200-day MA of 1.75, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 32.10 is Neutral, neither overbought nor oversold. The STOCH value of 20.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRQR.
ProQR Risk Analysis
ProQR disclosed 81 risk factors in its most recent earnings report. ProQR reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
ProQR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | $411.45M | -2.47 | -64.25% | ― | ― | -29.71% | |
56 Neutral | $708.05M | -13.53 | -16.59% | ― | 67.01% | 40.54% | |
52 Neutral | $225.77M | -3.67 | -68.44% | ― | 19.49% | -4.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $148.93M | -4.05 | -74.36% | ― | 35.89% | 58.70% | |
42 Neutral | $65.99M | -1.86 | -300.90% | ― | 0.99% | -3014.75% |
* Healthcare Sector Average
PRQR
ProQR
1.64
-0.72
-30.72%
CDXS
Codexis
1.36
-1.33
-49.44%
HRTX
Heron Therapeutics
0.35
-0.99
-74.10%
TLSA
Tiziana Life Sciences
1.12
-0.85
-43.15%
AVIR
Atea Pharmaceuticals
5.13
2.22
76.29%
OABI
OmniAb
4.87
3.19
189.88%
ProQR Corporate Events
ProQR Taps AI Leaders Chris Hart and Thomas Wolf to Accelerate Axiomer RNA Editing Pipeline
Sep 23, 2026
On September 23, 2026, ProQR announced it has appointed Chris Hart as Chief Data and AI Officer and added Hugging Face co-founder Thomas Wolf to its board as a strategic AI advisor, moves aimed at deepening the integration of artificial intelligen...
ProQR Doses First Participant in Phase 1 Trial of AX-0811 for Cholestatic Liver Diseases
Sep 9, 2026
On September 9, 2026, ProQR Therapeutics announced that it has dosed the first participant in a Phase 1 clinical trial of AX-0811, an AI-discovered RNA editing oligonucleotide designed to modulate NTCP as a potential disease-modifying treatment fo...
ProQR posts Q2 2026 results as Axiomer RNA editing gains first clinical validation
Aug 13, 2026
ProQR reported second-quarter 2026 results on August 13, 2026, highlighting its first clinical validation of the Axiomer platform via NTCP modulation with AX-0810 in a Phase 1 study in healthy volunteers. The company also emphasized its evolution ...
ProQR Reports Higher Revenue but Ongoing Losses in Second Quarter 2026 Results
Aug 13, 2026
On August 13, 2026, ProQR Therapeutics filed a Form 6-K and issued a press release reporting unaudited results for the three and six months ended June 30, 2026, along with a business update. The filing shows higher revenue versus the prior year pe...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.